<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Japan is one of the countries with lowest incidence rate of childhood type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> in the world, averaging 2.4 cases/100,000/year </plain></SENT>
<SENT sid="1" pm="."><plain>However, it appears that the prevalence of type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> in adulthood is more than twice compared to childhood patients </plain></SENT>
<SENT sid="2" pm="."><plain>There are at least three clinical subtypes of type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> in Japan, i.e. <z:hpo ids='HP_0011009'>acute-onset</z:hpo>, slow-<z:hpo ids='HP_0003674'>onset</z:hpo>, and fulminant type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Fulminant type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> is a unique subtype of type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> that accounts for about 20% of <z:hpo ids='HP_0011009'>acute-onset</z:hpo> type 1 <z:mp ids='MP_0002055'>diabetes</z:mp>, and is rare in childhood in Japan </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, the slow-<z:hpo ids='HP_0003674'>onset</z:hpo> form of type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> might be a major subtype of disease in adulthood </plain></SENT>
<SENT sid="5" pm="."><plain>In patients with <z:hpo ids='HP_0011009'>acute-onset</z:hpo> type 1 <z:mp ids='MP_0002055'>diabetes</z:mp>, about 90% of patients express at least one of GADAbs, <z:mp ids='MP_0004157'>IAA</z:mp>, and IA-2Abs at disease <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Slow-<z:hpo ids='HP_0003674'>onset</z:hpo> form of type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> is diagnosed as having type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> at disease <z:hpo ids='HP_0003674'>onset</z:hpo>, which is referred as "latent autoimmune <z:mp ids='MP_0002055'>diabetes</z:mp> in adults (LADA)", "GADAb(+) type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>", or "<z:hpo ids='HP_0003677'>slowly progressive</z:hpo> type 1 <z:mp ids='MP_0002055'>diabetes</z:mp>" </plain></SENT>
<SENT sid="7" pm="."><plain>The prevalence of GADAbs in adulthood patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> without insulin therapy is 3-4%, and is higher in the patients with shorter duration of <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>Although high levels of GADAbs are one of the predictive markers for future insulin requirement, there are a certain number of patients with high titer of GADAbs who do not progress to insulin dependency for many years, and the predictive value of GADAbs positivity for future insulin requirement is estimated about 67% by Baye's theory </plain></SENT>
<SENT sid="9" pm="."><plain>Thus, accurate predictive strategies of future insulin deficiency in LADA patients using autoantibody <z:chebi fb="0" ids="53000">epitope</z:chebi> analysis, genetic determination, or T cell assay are needed for the effective immune intervention </plain></SENT>
</text></document>